{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polymyalgia-rheumatica/management/management/","result":{"pageContext":{"chapter":{"id":"047c46a8-6c2e-538d-b303-898bc35b204c","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 2ff7e941-4ae7-4101-b34a-a7ba2fd64999 --><h2>Scenario: Management of polymyalgia rheumatica</h2><!-- end field 2ff7e941-4ae7-4101-b34a-a7ba2fd64999 -->","summary":"Covers the initial and ongoing management of polymyalgia rheumatic, including how to manage relapses and when to refer.","htmlStringContent":"<!-- begin item 870d5767-b539-4a2c-9d76-c78e19133879 --><!-- begin field d4be759f-ec20-4f83-96b4-acbc0155ae9d --><p>From age 40 years onwards.</p><!-- end field d4be759f-ec20-4f83-96b4-acbc0155ae9d --><!-- end item 870d5767-b539-4a2c-9d76-c78e19133879 -->","topic":{"id":"ce8b01ca-f53a-55a3-8d34-3f1c4627fe6a","topicId":"ad21d80a-1ea5-4ead-b50d-c84a90f81dfd","topicName":"Polymyalgia rheumatica","slug":"polymyalgia-rheumatica","lastRevised":"Last revised in January 2019","chapters":[{"id":"1422f739-c18d-5e1e-a304-97c38c53326d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"16d2834f-dff7-5cdb-a7f4-58e78255d2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0b8f18b-6f9c-5652-83d0-dafbd8f023f1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"45868673-afab-57d2-a5d7-8e82c7a6a1d6","slug":"changes","fullItemName":"Changes"},{"id":"5b1ee373-bd86-5e9d-812b-4832f6246571","slug":"update","fullItemName":"Update"}]},{"id":"27cf37e3-9a75-54bf-b40c-a9a5d3ab8774","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f98bc06e-32e0-5d1b-955b-704d835dadfc","slug":"goals","fullItemName":"Goals"},{"id":"de16a1ee-5b79-561d-aa33-007310d41806","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"27fd23e5-8ea0-5fc4-a238-92290ecf2d96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"07ae7b26-b61c-5b1d-a11a-2e2f8831b2b4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"40fc7a60-984c-568d-bca4-9c74b0dd12ad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"51474ce0-d36a-55b4-be78-dce9cacb0267","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"05f711b1-05e6-5832-a014-0d48622761aa","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2ff5c538-1fb7-5d1b-bd20-0b559053d445","slug":"definition","fullItemName":"Definition"},{"id":"222a21f0-7691-5217-92ac-d0b454809378","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"40912c6f-7953-5028-8087-bfe412fe8144","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c6caaf8-c9e3-5154-ad85-0639ce885933","slug":"complications","fullItemName":"Complications"},{"id":"7dad7582-0879-5b1d-a434-a7385c6bf62a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"f0e2a168-bba6-5e5e-9290-792a786adf37","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"18cd5747-18a3-56ba-bc8b-4426d03187a4","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"d17676a0-b0c6-5edc-8a36-71ff56514267","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5928ae5b-d1b2-5880-b5d0-520d3eefbbb3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"42122189-74ea-5630-87b7-23f6266addc0","fullItemName":"Management","slug":"management","subChapters":[{"id":"047c46a8-6c2e-538d-b303-898bc35b204c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ad839214-35b0-58d1-b8ec-1d66a6be3eb0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fa86dcab-a820-5a5f-a76d-e237364c1e7b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"caac4d3d-be17-58bd-b762-bb897b659611","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7cfd6eb7-5b49-52a2-aa31-f8bf0144547c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e0cae2d-7716-577b-8a6f-249f600698b5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8a07059-cd02-573a-819c-26383cacb522","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d99f4de4-aa27-5079-811c-923190c5046a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a29113d9-3ec2-598e-9d77-05509c1df517","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"42122189-74ea-5630-87b7-23f6266addc0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"f71b6cd1-51ea-5b8a-b2b8-5d003d90fd1b","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field 7f29fc22-43e7-459d-994a-61def0536a60 --><h3>How should I manage a person with polymyalgia rheumatica?</h3><!-- end field 7f29fc22-43e7-459d-994a-61def0536a60 -->","summary":null,"htmlStringContent":"<!-- begin item 34703eb4-c8df-4a24-b255-1f6732931ed5 --><!-- begin field afd6a8e0-6ce8-4c43-be83-0686bd2a3a88 --><p><strong>For people in whom a working <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/diagnosis/diagnosis/\">diagnosis</a> of polymyalgia rheumatica (PMR) has been made:</strong></p><ul><li><strong>Reduce the dose of prednisolone slowly when symptoms are fully controlled. </strong>A suggested schedule for reducing prednisolone is provided below, but smaller dose reductions and longer durations at each dose may be needed to avoid relapses in some people. Typically, treatment is required for between 1–2 years.<ul><li>For people who are well controlled on 15 mg daily, a suggested schedule is to:<ul><li>Continue prednisolone 15 mg each day until symptoms are fully controlled (usually 3 weeks), <em>then</em></li><li>Reduce the dose to 12.5 mg each day for 3 weeks, <em>then</em></li><li>Reduce the dose to 10 mg each day for 4–6 weeks, <em>then</em></li><li>Reduce the dose by 1 mg every 4–8 weeks until treatment is stopped.</li></ul></li><li>For information on prescribing prednisolone, including contraindications, adverse effects, and drug interactions, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li><li><strong>Ensure the person is provided with a blue steroid card</strong>, and discuss potential adverse effects of corticosteroids. In particular, advise them:<ul><li>Not to stop taking prednisolone abruptly and to seek medical advice if they are experiencing problems taking it.</li><li>To avoid close contact with people who have chickenpox, shingles, or measles if they do not have immunity to chickenpox or measles and to seek medical advice if they are exposed.</li></ul></li><li><strong>Provide written information </strong>on PMR and regional patient support groups.<ul><li>Polymyalgia Rheumatica and Giant Cell Arteritis (PMRGCA) UK (<a data-hyperlink-id=\"9cc53a05-095e-4fda-8b33-a98c00db304a\" href=\"http://www.pmrgcauk.com/\">www.pmrgcauk.com</a>) provide <a data-hyperlink-id=\"4d5c8529-02fe-4afe-bb0f-a9cd00d64699\" href=\"http://www.pmrgca.co.uk/info-pack/\">information packs</a>, a <a data-hyperlink-id=\"eeaf7c96-41ae-4d89-aaeb-a9cd00d646c9\" href=\"http://www.pmrgca.co.uk/content/helpline\">helpline</a>, <a data-hyperlink-id=\"90d3b920-9761-4d2c-bc01-a9cd00d646d4\" href=\"http://www.pmrgca.co.uk/downloads/1/\">newsletters</a>, <a data-hyperlink-id=\"ddcc1efd-9d11-4fac-8451-a9cd00d646e0\" href=\"http://www.pmrgca.co.uk/groups/\">support groups</a>, and a <a data-hyperlink-id=\"665621fa-b43b-4d2c-a8ab-a9cd00d646ec\" href=\"https://healthunlocked.com/pmrgcauk\" target=\"_blank\">web forum</a> for people with PMR and GCA. </li><li>Versus Arthritis (<a data-hyperlink-id=\"dfce99da-6927-4a11-acc9-a9cd00e92cac\" href=\"https://www.versusarthritis.org/\">www.versusarthritis.org</a>), formed in 2018 following a merger of Arthritis Care and Arthritis<a data-hyperlink-id=\"4da3800e-7c8e-4643-8adf-a9cd00e92ce2\" href=\"https://www.arthritisresearchuk.org/\" rel=\"noopener\" target=\"_blank\"> </a>Research UK, have information booklets on <a data-hyperlink-id=\"e1d08288-7a42-4e26-9df7-a9cd00e92d9c\" href=\"https://www.arthritisresearchuk.org/shop/products/publications/information-for-medical-professionals/hands-on/ho4-series-7.aspx\">Polymyalgia rheumatica</a> and <a data-hyperlink-id=\"1b5c67df-8e28-4a1f-aa76-a9cd00e92dd4\" href=\"https://www.arthritisresearchuk.org/shop/products/publications/patient-information/conditions/giant-cell-arteritis.aspx\">Giant cell arteritis</a>.</li></ul></li><li><strong>Arrange routine <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/management/management/#follow-up\">reviews</a> one week after any change in dose and at least every 3 months </strong>in the first year following diagnosis.</li><li><strong>Advise the person to arrange a <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/management/management/#follow-up\">review</a> at other times:</strong><ul><li>Urgently, if they develop symptoms of GCA.</li><li>Routinely, if they develop symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/management/management/#follow-up\">relapsing PMR</a>, including proximal pain, fatigue, and morning stiffness. </li></ul></li><li><strong>Refer for specialist management if:</strong><ul><li>It is not possible to reduce corticosteroids at reasonable intervals without causing relapse.</li><li>Corticosteroids are required for more than 2 years.</li><li>The person is experiencing (or is at high risk of) adverse effects from corticosteroids.</li></ul></li><li><strong>Assess and manage osteoporotic fracture risk. </strong>For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li></ul><!-- end field afd6a8e0-6ce8-4c43-be83-0686bd2a3a88 --><!-- end item 34703eb4-c8df-4a24-b255-1f6732931ed5 -->","subChapters":[{"id":"c3cc343b-327a-5ea8-9da7-685590b33bd0","slug":"basis-for-recommendation-467","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 355d6f6e-1d95-4cbd-b551-50c580758159 --><h4>Basis for recommendation</h4><!-- end field 355d6f6e-1d95-4cbd-b551-50c580758159 -->","summary":null,"htmlStringContent":"<!-- begin item 467092a2-e6ef-407c-9f73-815e1063291f --><!-- begin field a4c3f03d-5664-4078-a922-9a75570a85ca --><p>These recommendations are based on the <em>British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines for the management of polymyalgia rheumatica </em>(PMR) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>] and are supported by the <em>2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) collaborative initiative</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dejaco, 2015</a>] and expert opinion in review articles on PMR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Ameer, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Gonz&aacute;lez-Gay, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Matteson, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">BMJ Best Practice, 2018</a>].</p><h5>Prednisolone dose reduction</h5><ul><li>The dose of prednisolone should be reduced slowly because:<ul><li>Rapid withdrawal of long-term (more than 3 weeks) treatment with an oral corticosteroid may cause acute adrenal insufficiency (which can be fatal) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">BNF 76, 2018</a>].</li><li>Relapses are more likely to occur if corticosteroids are reduced or withdrawn too quickly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Gonz&aacute;lez-Gay, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">BMJ Best Practice, 2018</a>].</li><li>Rapid tapering of corticosteroids has been associated with longer duration of therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>].</li></ul></li><li>The suggested tapering schedule is based on the BSR/BHPR guideline. The guideline working group found evidence for a steroid regimen to be lacking and therefore based their suggested dosage regimen on a consensus decision. This guideline discussed the need for flexibility when tailoring treatment for an individual and acknowledges that, in practice, regimens may vary from the one suggested [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>].<ul><li>The EULAR/ACR guideline recommends using the minimum effective corticosteroid dose within a range of 12.5 mg–25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in people with a high risk of relapse and low risk of adverse events, whereas in people with relevant comorbidities (such as diabetes, osteoporosis, and glaucoma) and other risk factors for steroid-related adverse effects, a lower dose may be preferred. Daily doses of 7.5 mg or less or more than 30 mg are not recommended. The following principles of corticosteroid dose tapering are suggested in the guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dejaco, 2015</a>]:<ul><li>Initial tapering — dose should be tapered to an oral dose of 10 mg a day prednisone equivalent within 4–8 weeks.</li><li>Tapering once remission is achieved (following initial and relapse therapies) — daily oral prednisone should be tapered by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules, such as 10 mg/7.5 mg alternate days) until discontinuation given that remission is maintained.</li></ul></li><li>The schedules suggested by previous expert reviewers of this CKS topic varied considerably, and locally recommended schedules may differ.</li></ul></li><li>Some experts recommend the use of intramuscular methylprednisolone in milder cases of PMR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dejaco, 2015</a>]. However, intramuscular methylprednisolone is not routinely used in primary care.</li></ul><h5>Information and advice</h5><ul><li>CKS has extrapolated the advice on prednisolone treatment from information in the BSR/BHPR guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>].</li><li>Prolonged courses of corticosteroids increase susceptibility to infections and severity of infections.<ul><li>According to the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">BNF 76, 2018</a>]:<ul><li>People receiving oral or parenteral corticosteroids for purposes other than replacement should be regarded as being at risk of severe chickenpox unless they have had chickenpox. Passive immunization with varicella–zoster immunoglobulin is needed for exposed non–immune people receiving systemic corticosteroids or for those who have used them within the previous 3 months. Confirmed chickenpox warrants specialist care and urgent treatment.</li><li>People taking corticosteroids should be advised to take particular care to avoid exposure to measles and to seek immediate medical advice if exposure occurs. Prophylaxis with intramuscular normal immunoglobulin may be needed.</li></ul></li><li>According to the Public Health England (PHE) guideline <em>Varicella: the green book, chapter 34,</em> immunosuppression should be considered in people receiving 40 mg prednisolone for more than a week (more than the dose recommended in this topic), but there may occasionally be people on lower doses of corticosteroids who may be immunosuppressed and at increased risk from infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">PHE, 2015</a>].</li></ul></li></ul><h5>Follow up</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/management/management/#follow-up\">Follow up</a> for more information.</li></ul><h5>Osteoporosis prophylaxis</h5><ul><li>The recommendation to assess and treat osteoporotic fracture risk is consistent with UK guidelines from the National Institute for Health and Clinical Excellence (NICE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">NICE, 2012</a>] and the National Osteoporosis Guideline Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">NOGG, 2016</a>]. More detail on the evidence influencing their recommendations can be found in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li></ul><!-- end field a4c3f03d-5664-4078-a922-9a75570a85ca --><!-- end item 467092a2-e6ef-407c-9f73-815e1063291f -->","subChapters":[]}]},{"id":"76532420-cc56-5201-b790-25b68958af4f","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 0517a029-92c2-4347-8906-a9cd00d65d2d --><h3>How should I follow up a person with polymyalgia rheumatica?</h3><!-- end field 0517a029-92c2-4347-8906-a9cd00d65d2d -->","summary":null,"htmlStringContent":"<!-- begin item cf5c63ed-1ce8-4f1d-b3c4-a9cd00d65cf0 --><!-- begin field 0ee7cf66-b609-46ce-a11b-a9cd00d65d2d --><p><strong>Arrange routine reviews one week after any change in <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/management/management/#initial-management\">prednisolone dose</a> and at least every 3 months in the first year following diagnosis.</strong></p><ul><li><strong>At all routine reviews, </strong>ask about:<ul><li>Symptoms of giant cell arteritis (GCA), including an abrupt onset headache (usually temporal) and temporal tenderness, visual disturbance, or jaw or tongue claudication. If present, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/giant-cell-arteritis/\">Giant cell arteritis</a> for management information.</li><li>Relapsing symptoms of polymyalgia rheumatica, including proximal pain, fatigue, and morning stiffness. If present:<ul><li>Reassess the <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/diagnosis/diagnosis/\">diagnosis</a>.</li><li>Increase prednisolone to the previous dose that controlled symptoms, and monitor the response.</li><li>If symptoms settle, continue on this dose and consider <a class=\"topic-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/management/management/#initial-management\">tapering</a> the prednisolone dose more cautiously by increasing the scheduled dose durations or reducing the scheduled dose reductions to try to prevent further relapses.</li><li>If symptoms do not settle, seek specialist advice.</li></ul></li><li>Adverse effects of corticosteroids, such as weight gain, dyspepsia, muscle weakness, skin thinning and easy bruising.</li></ul></li><li><strong>At 3 monthly reviews, </strong>assess blood pressure and glucose, which may be adversely affected by corticosteroids.<ul><li>Only consider monitoring of full blood count (FBC) and urea and electrolytes if there is a clinical indication (for example, FBC if there is a suspicion of gastric bleeding secondary to corticosteroids; urea and electrolytes if concurrent prednisolone and diuretic use, or previously abnormal urea and electrolytes secondary to corticosteroids).</li></ul></li><li><strong>Refer for specialist management if:</strong><ul><li>It is not possible to reduce corticosteroids at reasonable intervals without causing relapse.</li><li>Corticosteroids are required for more than 2 years.</li><li>The person has repetitive flares.</li><li>The person is experiencing (or is at high risk of) adverse effects from corticosteroids.</li></ul></li></ul><!-- end field 0ee7cf66-b609-46ce-a11b-a9cd00d65d2d --><!-- end item cf5c63ed-1ce8-4f1d-b3c4-a9cd00d65cf0 -->","subChapters":[{"id":"be13ffa3-8374-5b84-8f2f-89791e4342c1","slug":"basis-for-recommendation-5be","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a5a208ae-88a1-4d3f-80b5-a9cd00d65d2f --><h4>Basis for recommendation</h4><!-- end field a5a208ae-88a1-4d3f-80b5-a9cd00d65d2f -->","summary":null,"htmlStringContent":"<!-- begin item 5befc240-1b2d-40d0-ac7e-a9cd00d65d2f --><!-- begin field 207bc08c-ed4c-4d28-9dce-a9cd00d65d2f --><p>These recommendations are based on the <em>British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines for the management of polymyalgia rheumatica </em>(PMR) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta, 2010</a>] and are supported by the <em>2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) collaborative initiative</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dejaco, 2015</a>].</p><h5>Frequency of review</h5><ul><li>The BSR/BHPR guidelines suggest, on the basis of expert opinion, follow up at 3, 6, 9, and 12 months in the first year, with additional visits if the person relapses or experiences adverse events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta, 2010</a>]. In the EULAR/ACR guideline, follow up visits are suggested every 4–8 weeks in the first year, every 8–12 weeks in the second year, and as indicated in case of relapse or as prednisone is tapered and discontinued [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dejaco, 2015</a>].</li><li>In addition, CKS recommends follow up after each dose change to identify any symptoms of relapse and to make any necessary adjustments to the withdrawal schedule.</li></ul><h5>Managing relapse</h5><ul><li>For the mangement of relapsing symptoms of PMR, the EULAR/ACR guideline recommends that oral prednisone should be increased to the pre-relapse dose and then decreased gradually (within 4–8 weeks) to the dose at which the relapse occurred [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dejaco, 2015</a>].</li></ul><h5>What to monitor</h5><ul><li>The BHR/BHPR guideline recommends monitoring symptoms, adverse effects of corticosteroids, and osteoporotic risk; reassessing the diagnosis; and monitoring blood tests, based on evidence from observational studies and the expert opinion of the guideline development group.<ul><li>The recommendation to monitor full blood count and urea and electrolytes depending on clinical judgement is pragmatic. CKS considers that routine monitoring of these parameters is unlikely to alter management of PMR, but these tests may help to inform the management of comorbid conditions.</li><li>Although a reduction in erythrocyte sedimentation rate (ESR) in response to prednisolone is useful in making a working diagnosis of PMR, an isolated raised ESR or C-reactive protein (CRP) once a diagnosis of PMR has been made is not a definite indicator of relapse (which is defined as recurrence of symptoms). CKS has therefore not recommended the routine monitoring of inflammatory markers.</li></ul></li><li>Expert opinion in review articles is that:<ul><li>When corticosteroids are tapered, disease flares may occur frequently (an average of 1–2 episodes per person-year) and are often manifested as new-onset or recurrent PMR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Weyand, 2014</a>].</li><li>Signs and symptoms of giant cell arteritis (GCA) should be monitored because GCA may manifest itself when the corticosteroids are tapered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">BMJ Best Practice, 2018</a>].</li></ul></li></ul><!-- end field 207bc08c-ed4c-4d28-9dce-a9cd00d65d2f --><!-- end item 5befc240-1b2d-40d0-ac7e-a9cd00d65d2f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}